Skip to main content

Diffuse Large B-Cell Lymphoma


True or False: For patients with DLBCL, health care resource utilization and costs are greater for hematopoietic cell transplant compared with CAR-T therapy.
The rate of surveillance imaging of survivors of DLBCL decreased after the American Society of Hematology (ASH)…
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation…
Conference Coverage
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and…
Conference Coverage
Study results show polatuzumab vedotin plus bendamustine-rituximab is cost-effective in comparison to bendamustine-…
Back to Top